Report of Foreign Issuer (6-k)
May 18 2020 - 7:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of May 2020
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in
its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
The first and second paragraph and the
bullet language below the second paragraph of the press release attached to this Form 6-K are hereby incorporated by reference
into the registrant’s Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124, 333-236064,
333-209037 and 333-220644), to be a part thereof from the date on which this report is submitted, to the extent not superseded
by documents or reports subsequently filed or furnished.
On May 18, 2020, Can-Fite BioPharma Ltd. issued a press release
announcing additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver
disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH). A copy of this press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: May 18, 2020
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Sep 2024